International Journal of Molecular Sciences · 2021 · 10 citations · 24 references
PharmacyOncologyPharmacologyChemotherapyDrug DeliveryNanomaterialsCancer NanomedicineInorganic NanoparticlesNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignAnticancer ActivityAnticancer ChemotherapyCancer NanotherapyCombination TherapyIron Oxide NanoparticlesMagnetic Nanoparticle Drug CarriersNanoparticle-based ChemotherapyPolymeric Nanoparticle Toxicity
One of the promising strategies for improvement of cancer treatment is application of a combination therapy. The aim of this study was to investigate the anticancer activity of nanoformulations containing doxorubicin and iron oxide particles covered with polymeric shells bearing cholesterol moieties. It was postulated that due to high affinity to cell membranes, particles comprising poly(cholesteryl acrylate) can sensitize cancer cells to doxorubicin chemotherapy. The performed analyses revealed that the developed systems are effective against the human breast cancer cell lines MCF-7 and MDA-MB-231 even at low doses of the active compound applied (0.5 µM). Additionally, high compatibility and lack of toxicity of the tested materials against human red blood cells, immune (monocytic THP-1) cells, and cardiomyocyte H9C2(2-1) cells was demonstrated. Synergistic effects observed upon administration of doxorubicin with polymer-iron oxide hybrids comprising poly(cholesteryl acrylate) may provide an opportunity to limit toxicity of the drug and to improve its therapeutic efficiency at the same time.
24
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller, Letícia Nogueira, Angela B. Mariotto et al. · CA A Cancer Journal for Clinicians · 2019 · 4.4K citations · Full text
Caroline F. Thorn, Connie Oshiro, Sharon Marsh et al. · Pharmacogenetics and Genomics · 2010 · 1.6K citations · Full text
MICROCIRCULATION AND HEMORHEOLOGY
Aleksander S. Popel, Paul C. Johnson · Annual Review of Fluid Mechanics · 2005 · 813 citations · Full text
The anthracyclines: will we ever find a better doxorubicin?
PubMed · 1992 · 559 citations
Medicine, Oncology, Pharmacology +16